Abstract library

24 results for "Gherlan".
#1679 Management of Neuroendocrine Tumors in the Netherlands
Introduction: To determine optimal management of patients with pancreatic neuroendocrine tumors (pNETs), more insight in the prognosis and treatment outcomes is needed.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D. Cansu Genc
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler
#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey
Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Sonja Levy
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1792 Treatment and Survival of 351 Patients Diagnosed with Merkel Cell Carcinoma in 2 Melanoma and Neuroendocrine Tumor Expert-Centers in the Netherlands
Introduction: Merkel cell carcinoma (MCC) is a rare and potentially aggressive neuroendocrine carcinoma of the skin. Because of its frequency, adequate data on treatment and survival are lacking.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MSc Linde M van Veenendaal
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#1418 Extra-Pulmonary Neuroendocrine Carcinomas: A National Population Based Study
Introduction: Extra pulmonary neuroendocrine carcinomas(EPNEC) are rare tumours, this implies lack of knowledge on the burden.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MSc. Jan Maarten Van Der Zwan
Keywords: EP-NEC
#333 Sporadic Hypercalcitoninemia: Thyroid Medullary carcinoma, Autoimmune Thyroiditis or GLP-1 Agonists’ Effect?
Introduction: Glucagon-like peptide 1 (GLP-1) receptor agonists’ stimulated C-cell hyperplasia and tumors in rodents, but not in humans. Calcitonin also increased in autoimmune thyroid disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Raluca A. Trifanescu
#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#206 Diverging Incidence and Survival Trends for Neuroendocrine Tumors due to Histological Grade
Introduction: Epidemiological data of NET are mostly classified according to the primary site of the tumor. However, a pathologic classification, irrespective of primary site, might be more informative.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Catharina M Korse